Related Experiment Video
Updated: Jun 16, 2026
07:14
Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
Published on: July 11, 2025
A cell-based high-throughput screen validates the plasmodial surface anion channel as an antimalarial target
Ajay D Pillai1, Margaret Pain, Tsione Solomon
1Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852-8132, USA.
Molecular Pharmacology
|January 27, 2010
Summary
Researchers identified novel, potent inhibitors of the plasmodial surface anion channel (PSAC), a key target in malaria parasites. These compounds validate PSAC as an antimalarial drug target and offer new research tools.
Area of Science:
- Parasitology
- Ion Channel Biology
- Drug Discovery
Background:
- The plasmodial surface anion channel (PSAC) is crucial for malaria parasite survival within erythrocytes.
- Existing PSAC inhibitors lack high affinity and specificity, necessitating new drug development strategies.
Purpose of the Study:
- To identify novel, high-affinity inhibitors of PSAC.
- To validate PSAC as a druggable target for antimalarial drug development.
Main Methods:
- Development of a miniaturized PSAC activity assay.
- High-throughput screening of approximately 70,000 compounds.
- Single-channel patch-clamp electrophysiology and in vitro parasite killing assays.
Main Results:
- Discovery of novel heterocyclic scaffolds with potent PSAC inhibitory activity.
- Demonstration that identified inhibitors act directly on PSAC.
- Chemical validation of PSAC as an antimalarial drug target through correlation of inhibition and parasite killing.
Conclusions:
- Novel inhibitors targeting PSAC have been identified.
- These compounds represent promising starting points for developing new antimalarial drugs.
- PSAC is a validated and druggable target for malaria treatment.
